HHS has issued guidance aimed at blocking drug companies from manipulating a loophole in Medicaid’s payment policies that they can use to avoid paying out full rebates for certain medications.
Azar: New HHS guidance aimed at curbing drug companies’ ‘abusive behavior’ in Medicaid
